MedTrace Logo

Steroid-reducing Effects of Crisaborole

NCT03832010 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-07-19

Study results available
· View outcomes & findings →

Summary

Atopic dermatitis, or eczema, is a chronic skin condition affecting many children. Crisaborole is a non-steroid topical medication which is FDA approved for children aged 2 and older for eczema. This research study seeks to investigate whether crisaborole reduces topical steroid use in children with atopic dermatitis.

Conditions

Interventions

DRUG

Crisaborole

Participants will be instructed to apply crisaborole to affected areas with eczema.

DRUG

Hydrocortisone Ointment

Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.

DRUG

Triamcinolone ointment

Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.

DRUG

Aquaphor

Participants will be instructed to moisturize all over the body with Aquaphor.

Sponsors & Collaborators

Principal Investigators

  • Anna Grossberg, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2024-02-16
Completion
2024-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03832010 on ClinicalTrials.gov